Relationship between SLC6A3 genotype and striatal dopamine transporter availability: A meta-analysis of human single photon emission computed tomography studies

Synapse

Volumn 65, Issue 10, 2011, Pages 998-1005

  Costa, Anna ^a   Riedel, Michael ^a,b   Müller, Ulrich ^c   Möller, Hans Jürge ^a   Ettinger, Ulrich ^a,d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Gerontopsychiatrie und Neurologie   (Germany)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

Caudate; Dopamine; Genetics; Human; Putamen; SLC6A3; SPECT

Indexed keywords

DOPAMINE TRANSPORTER;

ARTICLE; ATTENTION DEFICIT DISORDER; CORPUS STRIATUM; GENE; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLC 6A3 GENE; VARIABLE NUMBER OF TANDEM REPEAT;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GENOTYPE; HUMANS; MINISATELLITE REPEATS; PARKINSON DISEASE; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 79960951909     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20927     Document Type: Article

References (51)

1. Abi-Dargham A, Gandelman MS, DeErausquin GA, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Laruelle M, Charney DS, Hoffer PB, Neumeyer JL, Innis RB. 1996. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med 37: 1129-1133.
2. Bannon MJ, Michelhaugh SK, Wang J, Sacchetti P. 2001. The human dopamine transporter gene: Gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. Eur Neuropsychopharmacol 11: 449-455.
3. Barr CL, Xu C, Kroft J, Feng Y, Wigg K, Zai G, Tannock R, Schachar R, Malone M, Roberts W, Nothen MM, Grunhage F, Vandenbergh DJ, Uhl G, Sunohara G, King N, Kennedy JL. 2001. Haplotype study of three polymorphisms at the dopamine transporter locus confirm linkage to attention-deficit/hyperactivity disorder. Biol Psychiatry 49: 333-339.
4. Caldu X, Vendrell P, Bartres-Faz D, Clemente I, Bargallo N, Jurado MA, Serra-Grabulosa JM, Junque C. 2007. Impact of the COMT Val108/158 Met and DAT genotypes on prefrontal function in healthy subjects. Neuroimage 37: 1437-1444.
5. Cheon KA, Ryu YH, Kim JW, Cho DY. 2005. The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: Relating to treatment response to methylphenidate. Eur Neuropsychopharmacol 15: 95-101.
6. Contin M, Martinelli P, Mochi M, Albani F, Riva R, Scaglione C, Dondi M, Fanti S, Pettinato C, Baruzzi A. 2004. Dopamine transporter gene polymorphism, spect imaging, and levodopa response in patients with Parkinson disease. Clin Neuropharmacol 27: 111-115.
7. Cook EH, Jr., Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE, Leventhal BL. 1995. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 56: 993-998.
8. Cravchik A, Goldman D. 2000. Neurochemical individuality: Genetic diversity among human dopamine and serotonin receptors and transporters. Arch Gen Psychiatry 57: 1105-1114.
9. DerSimonian R, Laird N. 1986. Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
10. Doucette-Stamm LA, Blakely DJ, Tian J, Mockus S, Mao JI. 1995. Population genetic study of the human dopamine transporter gene (DAT1). Genet Epidemiol 12: 303-308.
11. Dreher JC, Kohn P, Kolachana B, Weinberger DR, Berman KF. 2009. Variation in dopamine genes influences responsivity of the human reward system. Proc Natl Acad Sci USA 106: 617-622.
12. Drgon T, Lin Z, Wang GJ, Fowler J, Pablo J, Mash DC, Volkow N, Uhl GR. 2006. Common human 5' dopamine transporter (SLC6A3) haplotypes yield varying expression levels in vivo. Cell Mol Neurobiol 26: 875-889.
13. Ettinger U, Schmechtig A, Toulopoulou T, Borg C, Orrells C, Owens S, Matsumoto K, van Haren NE, Hall MH, Kumari V, McGuire PK, Murray RM, Picchioni M. in press. Prefrontal and striatal volumes in monozygotic twins concordant and discordant for schizophrenia. Schizophr Bull.
14. Franke P, Schwab SG, Knapp M, Gansicke M, Delmo C, Zill P, Trixler M, Lichtermann D, Hallmayer J, Wildenauer DB, Maier W. 1999. DAT1 gene polymorphism in alcoholism: A family-based association study. Biol Psychiatry 45: 652-654.
15. Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S. 2001. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenom J 1: 152-156.
16. Garris PA, Wightman RM. 1994. Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: An in vivo voltammetric study. J Neurosci 14: 442-450.
17. Gelernter J, Kranzler H, Lacobelle J. 1998. Population studies of polymorphisms at loci of neuropsychiatric interest (tryptophan hydroxylase (TPH), dopamine transporter protein (SLC6A3). D3 dopamine receptor (DRD3), apolipoprotein E (APOE), mu opioid receptor (OPRM1), and ciliary neurotrophic factor (CNTF)). Genomics 52: 289-297.
18. Gill M, Daly G, Heron S, Hawi Z, Fitzgerald M. 1997. Confirmation of association between attention deficit hyperactivity disorder anda dopamine transporter polymorphism. Mol Psychiatry 2: 311-313.
19. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. 1996. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379: 606-612.
20. Gorroochurn P, Hodge SE, Heiman G, Greenberg DA. 2004. Effect of population stratification on case-control association studies. II. False-positive rates and their limiting behavior as number of subpopulations increases. Hum Hered 58: 40-48.
21. Hedges LV, Olkin I. 1985. Statistical methods for meta-analysis/LarryV. Hedges, Ingram Olkin. Orlando: Academic Press. xxii, 369p.
22. Heinz A, Ragan P, Jones DW, Hommer D, Williams W, Knable MB, Gorey JG, Doty L, Geyer C, Lee KS, Coppola R, Weinberger DR, Linnoila M. 1998. Reduced central serotonin transporters in alcoholism. Am J Psychiatry 155: 1544-1549.
23. Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, Gorey JG, Lee KS, Linnoila M, Weinberger DR. 2000a. Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 22: 133-139.
24. Heinz A, Jones DW, Mazzanti C, Goldman D, Ragan P, Hommer D, Linnoila M, Weinberger DR. 2000b. A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry 47: 643-649.
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG. 2003. Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
26. Iversen LL. 1971. Role of transmitter uptake mechanisms in synaptic neurotransmission. Br J Pharmacol 41: 571-591.
27. Jacobsen LK, Staley JK, Zoghbi SS, Seibyl JP, Kosten TR, Innis RB, Gelernter J. 2000. Prediction of dopamine transporter binding availability by genotype: A preliminary report. Am J Psychiatry 157: 1700-1703.
28. Kang AM, Palmatier MA, Kidd KK. 1999. Global variation of a 40-bp VNTR in the 3'-untranslated region of the dopamine transporter gene (SLC6A3). Biol Psychiatry 46: 151-160.
29. Krause J, Dresel SH, Krause KH, La Fougere C, Zill P, Ackenheil M. 2006. Striatal dopamine transporter availability and DAT-1 gene in adults with ADHD: No higher DAT availability in patients with homozygosity for the 10-repeat allele. World J Biol Psychiatry 7: 152-157.
30. Lafuente A, Bernardo M, Mas S, Crescenti A, Aparici M, Gasso P, Catalan R, Mateos JJ, Lomena F, Parellada E. 2007. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics. Schizophr Res 90: 115-122.
31. Lynch DR, Mozley PD, Sokol S, Maas NM, Balcer LJ, Siderowf AD. 2003. Lack of effect of polymorphisms in dopamine metabolism related genes on imaging of TRODAT-1 in striatum of asymptomatic volunteers and patients with Parkinson's disease. Mov Disord 18: 804-812.
32. Martinez D, Broft A, Laruelle M. 2001a. Imaging neurochemical endophenotypes: Promises and pitfalls. Pharmacogenomics 2: 223-237.
33. Martinez D, Gelernter J, Abi-Dargham A, van Dyck CH, Kegeles L, Innis RB, Laruelle M. 2001b. The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology 24: 553-560.
34. Mignone F, Gissi C, Liuni S, Pesole G. 2002. Untranslated regions of mRNAs. Genome Biol 3: REVIEWS0004.
35. Mill J, Asherson P, Craig I, D'souza UM. 2005. Transient expression analysis of allelic variants of a VNTR in the dopamine transporter gene (DAT1). BMC Genet 6: 3.
36. Miller GM, Madras BK. 2002. Polymorphisms in the 3'-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression. Mol Psychiatry 7: 44-55.
37. Mitchell RJ, Howlett S, Earl L, White NG, McComb J, Schanfield MS, Briceno I, Papiha SS, Osipova L, Livshits G, Leonard WR, Crawford MH. 2000. Distribution of the 3' VNTR polymorphism in the human dopamine transporter gene in world populations. Hum Biol 72: 295-304.
38. Nakamura Y, Koyama K, Matsushima M. 1998. VNTR (variable number of tandem repeat) sequences as transcriptional, translational, or functional regulators. J Hum Genet 43: 149-152.
39. Neumeyer JL, Wang S, Gao Y, Milius RA, Kula NS, Campbell A, Baldessarini RJ, Zea-Ponce Y, Baldwin RM, Innis RB. 1994. N-omega-fluoroalkyl analogs of (1R)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)-tropane (beta-CIT): Radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem 37: 1558-1561.
40. Nutt JG, Carter JH, Sexton GJ. 2004. The dopamine transporter: Importance in Parkinson's disease. Ann Neurol 55: 766-773.
41. Parsian A, Zhang ZH. 1997. Human dopamine transporter gene polymorphism (VNTR) and alcoholism. Am J Med Genet 74: 480-482.
42. Praschak-Rieder N, Kennedy J, Wilson AA, Hussey D, Boovariwala A, Willeit M, Ginovart N, Tharmalingam S, Masellis M, Houle S, Meyer JH. 2007. Novel 5-HTTLPR allele associates with higher serotonin transporter binding in putamen: A [(11)C] DASB positron emission tomography study. Biol Psychiatry 62: 327-331.
43. Sano A, Kondoh K, Kakimoto Y, Kondo I. 1993. A 40-nucleotide repeat polymorphism in the human dopamine transporter gene. Hum Genet 91: 405-406.
44. van de Giessen EM, de Win MM, Tanck MW, van den Brink W, Baas F, Booij J. 2009. Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3. J Nucl Med 50: 45-52.
45. van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Staley JK, Laruelle M, Baldwin RM, Innis RB, Gelernter J. 2005. Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med 46: 745-751.
46. Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW, Uhl GR. 1992. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 14: 1104-1106.
47. VanNess SH, Owens MJ, Kilts CD. 2005. The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet 6: 55.
48. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley SJ, Hitzemann R, Smith G, Fields SD, Gur R. 1996. Dopamine transporters decrease with age. J Nucl Med 37: 554-559.
49. Willeit M, Praschak-Rieder N. 2010. Imaging the effects of genetic polymorphisms on radioligand binding in the living human brain: A review on genetic neuroreceptor imaging of monoaminergic systems in psychiatry. Neuroimage 53: 878-892.
50. Willeit M, Stastny J, Pirker W, Praschak-Rieder N, Neumeister A, Asenbaum S, Tauscher J, Fuchs K, Sieghart W, Hornik K, Aschauer HN, Brucke T, Kasper S. 2001. No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism. Biol Psychiatry 50: 8-12.
51. Wong DF, Pearlson GD, Tune LE, Young LT, Meltzer CC, Dannals RF, Ravert HT, Reith J, Kuhar MJ, Gjedde A. 1997. Quantification of neuroreceptors in the living human brain. IV. Effect of aging and elevations of D2-like receptors in schizophrenia and bipolar illness. J Cereb Blood Flow Metab 17: 331-342.